title: When is antidepressant polypharmacy appropriate in the treatment of depression?
abstract: Depression is a serious medical condition that is often only partially improved or completely unchanged after standard treatment with antidepressant medications. Various approaches have been developed to treat this subgroup of individuals with 'treatment-resistant' depression; but many individuals continue to live with chronic depressive symptoms that seriously affect their quality of life and overall functioning. One relatively new strategy is 'antidepressant polypharmacy' - simultaneously administering two or more antidepressant medications. Given the heterogeneity of the etiology of depression, this approach could improve therapeutic outcomes by concurrently activating multiple neurological pathways with different mechanisms of action, but there is also the risk that using multiple antidepressants would increase the prevalence and severity of side effects. Further work is needed to assess the potential benefits and risks of this strategy to managing treatmentresistant depression.
authors: Beijing Shijitan Hospital, Capital University of Medical Sciences, Beijing, China.
authors: Tianmei
authors: T
authors: Si
authors: Beijing Shijitan Hospital, Capital University of Medical Sciences, Beijing, China.
authors: Ping
authors: P
authors: Wang
keywords: adjunctive treatment; antidepressants; depression; multimodal treatment; polypharmacy; treatment-resistant depression
references: J Clin Psychopharmacol. 1999 Apr;19(2):177-82
references: 10211920
references: J Clin Psychopharmacol. 1997 Aug;17(4):284-91
references: 9241008
references: Biol Psychiatry. 2004 Feb 1;55(3):296-300
references: 14744472
references: J Clin Psychiatry. 2010 Aug;71(8):971-5
references: 20797377
references: Int J Clin Pract. 2007 Dec;61(12):2030-40
references: 17944926
references: Am J Psychiatry. 2010 Mar;167(3):281-8
references: 20008946
references: Am J Psychiatry. 2006 Nov;163(11):1905-17
references: 17074942
references: Curr Psychiatry Rep. 2013 Oct;15(10):403
references: 24052267
references: Am J Psychiatry. 2010 Mar;167(3):241-3
references: 20194484
references: Int J Neuropsychopharmacol. 2014 Jul;17(7):1009-37
references: 23719026
references: Eur Neuropsychopharmacol. 2009 Jul;19(7):457-65
references: 19345072
references: Am J Psychiatry. 2011 Jul;168(7):689-701
references: 21536692